Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

Exclusion Criteria

• •1. Has an elevated oral temperature (≥38°C or 100.4°F) within 3 days of the intended date of vaccination.
• •2. Known hypersensitivity or allergy to any of the vaccine components (including excipients of the investigational vaccine or placebo).
• •3. Has any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (e.g., Guillain-Barré syndrome).
• •4. Known or suspected impairment/alteration of immune function, including:
• •1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (M0) (use of inhaled, intranasal, or topical corticosteroids is allowed)
• •2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks/≥ 2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (M0).
• •3. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (M0) or planned administration during the trial.
• •4. Receipt of immunostimulants within 60 days prior to Day 1 (M0).
• •5. Hepatitis C virus infection.
• •6. Genetic immunodeficiency.
• •5. Has abnormalities of splenic or thymic function.
• •6. Has a known bleeding diathesis, or any condition that may be associated with a prolonged bleeding time.
• •7. Has any serious chronic or progressive disease according to judgment of the Investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
• •8. Has body mass index (BMI) greater than or equal to 35 kg/m\^2 (= weight in kg/\[height in meters\^2\]).
• •9. Has history of substance or alcohol abuse within the past 2 years.
• •10. Had previous and planned vaccination (during the trial conduct) against any flavivirus including dengue, yellow fever (YF), Japanese encephalitis (JE) viruses or tick-borne encephalitis.
• •11. Has a current or previous infection with a flavivirus such as dengue, Zika, YF, JE, West Nile (WN) fever, tick-borne encephalitis or Murray Valley encephalitis and participants with a history of prolonged (≥1 year) habitation in a dengue endemic area.